Biotech | August 08, 2021
TAKE divests stake in Navitas Life Sciences to HIG
The transaction is expected to close in the Q4FY22
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
AstraZeneca, Sinopharm and Moderna were part of the study
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Subscribe To Our Newsletter & Stay Updated
